Skip to search formSkip to main contentSkip to account menu

sotrastaurin

An orally available pan-protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Sotrastaurin inhibits both T… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (1)

AEB071
NCIt Antineoplastic Agent TerminologySotrastaurin Acetate

Broader (2)

PyrrolesQuinazolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
NF-κB signaling and its relevance to the treatment of mantle cell lymphoma
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined… 
Review
2018
Review
2018
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma.
Highly Cited
2015
Highly Cited
2015
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
2015
2015
Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.
Docetaxel (DTX), a taxane drug, has widely been used as an anticancer or antiangiogenesis drug. However, DTX caused side effects… 
2014
2014
Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.
9030 Background: Uveal melanoma is characterized by frequent mutations in GNAQ or GNA11 that encode for G-protein α-subunits (G… 
Highly Cited
2013
Highly Cited
2013
Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive malignancy that is characterized by poor prognosis. Large-scale pharmacological… 
Review
2012
Review
2012
Current state of renal transplant immunosuppression: Present and future.
For kidney transplant recipients, immunosuppression commonly consists of combination treatment with a calcineurin inhibitor, an… 
Highly Cited
2011
Highly Cited
2011
Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients
Sotrastaurin, a selective protein‐kinase‐C inhibitor, blocks early T‐cell activation through a calcineurin‐independent mechanism… 
Highly Cited
2011
Highly Cited
2011
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
The activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) correlates with poor prognosis. The ABC subtype… 
Highly Cited
2010
Highly Cited
2010
Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients
Sotrastaurin, a novel protein‐kinase‐C inhibitor, blocks early T‐cell activation. In this 12‐month, Phase II study, de novo renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)